Healthcare Professionals   /   Conferences   /   Conference and Meeting Announcements   /   2002   /   September

The 2nd Princess Margaret Hospital Conference on New Developments in Cancer Management

Last Modified: June 30, 2002

Conference Dates: September 19 - 21, 2002
Conference Location: Toronto, Ontario Canada

Sponsoring Group: Princess Margaret Hospital and Imedex, Inc.

Conference Web Page URL: http://www.imedex.com/Imedex%20website/images/Flash/pmh02.htm

Topics Covered: Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer, Breast Cancer, Hematologic Malignancies, Genito-urinary Cancer, Gynecological Cancers, Imaging, Supportive Care

Conference Objectives: To update attendees on standard cancer therapies, new experimental programs and advances in supportive care, which they may consider to apply in the treatment of their cancer patients

Who Should Attend: physicians, nurses and other health care practioners working in cancer treatment

Conference Agenda: SCIENTIFIC PROGRAM Thursday, September 19, 2002 11:00 am Welcome and Introduction 11:10 am Genes, proteins and people: The impact of novel technology on target discovery Christopher Paige 12 noon Lunch Symposium Supported by Ortho Biotech Session I: Lung Cancer 1:00 pm CT Screening for lung cancer. Are the current studies definitive? Jane Crossin 1:20 pm Combined modality therapy for stage III non-small cell lung cancer Ronald L. Burkes 1:40 pm Targeted therapy for non-small cell lung cancer Joan H. Schiller 2:00 pm Is there a role for surgery in the treatment of mesothelioma? Michael R. Johnston 2:20 pm Q&A Session II: Gastrointestinal Cancer 2:30 pm Surgical aspects of esophageal cancer treatment Gail E. Darling 2:45 pm Adjuvant treatment for esophageal cancer Rebecca Wong 3:00 pm Q&A 3:05 pm Surgical aspects of stomach cancer treatment Rod E. Schwarz 3:20 pm Adjuvant therapy for stomach cancer Jolie Ringash 3:35 pm Q&A 3:40 pm Break 4:00 pm Surgery for pancreatic cancer Murray F. Brennan 4:15 pm Adjuvant and advanced pancreatic cancer treatment Malcolm Moore 4:30 pm Q&A Session III: Head and Neck Cancer 4:35 pm New approaches to surgical reconstruction of the larynx Ralph W. Gilbert 4:50 pm New concepts in oromandibular reconstruction Peter C. Neligan 5:05 pm Altered fractionation and new concepts in precision radiotherapy in head and neck malignancies Brian O?Sullivan 5:20 pm Chemotherapy in the management of head and neck malignancy Lilian Siu 5:35 pm Panel discussion: The management of advanced head and neck cancer: What are the options? Moderator: Jonathan C. Irish Panel Members: Brian O?Sullivan, John Waldron, Lillian Siu, Ian F. Tannock, and Patrick J. Gullane 6:00 pm Evening Symposium Friday, September 20, 2002 7:00 am Breakfast Symposium 8:00 am Session IV: Breast Cancer 8:00 am Aromatase inhibitors in breast cancer prevention and adjuvant therapy. Paul E. Goss 8:20 am Micrometastases in lymph nodes and bone marrow: Implications for therapy Michael Crump 8:40 am Managing side effects of adjuvant therapy Charles L. Loprinzi 9:00 am Regional radiation as part of adjuvant therapy for 1-3 positive axillary nodes: Should it be the standard of care? Katherine Vallis 9:20 am Q&A 9:30 am Break Session V: Supportive Care Program 10:00 am Contemporary indications and expectations from palliative radiotherapy Rebecca Wong 10:20 am Palliative surgical interventions for cancer patients Alexandra M. Easson 10:40 am Fungal infections: What is new in 2002? Coleman Rotstein 11:00 am Management of mucositis in cancer patients. What is new in 2002? Edward B. Rubenstein 11:20 am Are bisphosphonates all that they are cracked up to be? David Warr 11:40 am Q&A 12:00 noon Lunch Symposium Supported by AstraZeneca Session VI: Hematologic Malignancies (part A) 1:00 pm Acute leukemia in the elderly Richard A.Wells 1:20 pm Chronic myeloid leukemia: Therapy in evolution Jeffrey H. Lipton 1:40 pm Pathogenesis and therapeutic options of myelodysplasia Elihu Estey 2:00 pm Update on myeloma therapy A. Keith Stewart 2:20 pm Q&A 2:30 pm Break Session VII: Hematologic Malignancies (part B) 3:00 pm The power of molecular diagnostics in the management of NHL Margaret A. Shipp 3:20 pm Novel therapies in the management of NHL Michael Crump 3:40 pm The role of radiotherapy in Hodgkin?s disease Mary Gospodarowicz 4:00 pm Biology and management of CLL John G. Gribben 4:20 pm Q&A 4:30 pm Evening Symposium Saturday, September 21, 2002 8:00 am Session VIII: Imaging 8:00 am New advances in breast imaging Christine Wilson 8:20 am PET Scanning 9:00 am Q&A Session IX: Genito-urinary Cancer 9:10 am New targets for prostate cancer chemotherapy Philip Kantoff 9:30 am Management of the primary tumour in patients with metastatic renal cell carcinoma. Michael Jewett 9:50 am High-precision RT and beyond for localised prostate cancer Charles Catton 10:10 am Reassessing the role of chemotherapy in advanced bladder cancer. Malcolm Moore 10:30 am Q&A 10:50 am Break Session X: Gynecological Cancers 11:10 am Can ovarian cancer be prevented? Barry Rosen 11:30 am Debate: Radiation and surgery are of unproven value in the curative treatment of ovarian cancer. Pro: Ken Swenerton and Jeremy F. Sturgeon Con: Joan Murphy and Anthony W. Fyles 12:00 noon Novel therapeutics in ovarian cancer Amit M. Oza 12:15 pm Palliative surgery in ovarian cancer Denny DePetrillo 12:30 pm Conclusion and farewell Ronald Feld

Registration Information: Register by phone to 770-751-7332, fax: 770-751-7334, email: meetings@imedex.com, online at www.imedex.com

Conference Fees: Physicians: $225+, Nurses, Fellows and Residents: $125+

Continuing Education: Yes

Miscellany: CME: 16 hours, category 1 AMA-PRA and Royal College of Physicians and Surgeons of Canada

Conference Dates: October 3, 2002
Conference Location: Marquis Ballroom, Marriott Marquis, 1535 Broadway, New York, New York, USA

Sponsoring Group: The Multiple Myeloma Research Foundation

Conference Web Page URL: www.multiplemyeloma.org

Topics Covered: bisphosphonates

• thalidomide
• novel therapies
• genetics
• transplantation
• current approaches in the treatment of multiple myeloma chemotherapy

Conference Objectives: To provide patients, family and friends with a comprehensive overview of the latest biological and clinical research information on myeloma.

Who Should Attend: patient, patient family and friends

Conference Agenda:

• 4:15-5 - Dr. David Roodman, bisphosphonates
• 5-5:45 - Dr. Bart Barlogie, transplantation
• 5:45-6:15- break
• 6:15-7 - Dr. Bergsagel, genetics
• 7-7:45 Dr. Ken Anderson, novel therapies
• 7:45-8:30 - Dr. Ruben Niesvizky,
• current approaches to myeloma
• 8:30-9 - Additional Q&A

Registration Information: Please contact Sarah Davis at the Multiple Myeloma Research Foundation at 203-972-1250 or email daviss@themmrf.org.

Conference Fees: Free

Continuing Education: No